Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-02)
NCT04221152Phase 3Unknown
- Sponsor
- Kobe University
- Start
- Feb 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in diabetes mellitus (DM), insulin resistance syndrome, lipoatrophic diabetes mellitus, Type A insulin resistance syndrome (TAIRS), Type B Insulin Resistance Syndrome (TBIRS), sponsored by Kobe University. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
diabetes mellitus (DM)insulin resistance syndromelipoatrophic diabetes mellitusType A insulin resistance syndrome (TAIRS)Type B Insulin Resistance Syndrome (TBIRS)
Beyond the preview
Go deeper on NCT04221152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221152.